Guggenheim Sees Biogen (BIIB) Down 15-20% After 'Worst Fears Come True'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright
March 25, 2019 7:49 AM EDTH.C. Wainwright analyst Andrew Fein lowered the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $363.00) while maintaining a Buy rating following the discontinuation of Aducanumab. Despite limited details around the data, Fein thinks this development nevertheless points to the insufficiency in the current... More
Mizuho Securities Downgrades Biogen (BIIB) to Neutral
March 21, 2019 10:06 AM EDTMizuho Securities analyst Salim Syed downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral with a price target of $235.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $320.59 yesterday.
... MoreBiogen (BIIB) PT Lowered to $275 at Cowen
March 21, 2019 9:20 AM EDTCowen analyst Phil Nadeau lowered the price target on Biogen (NASDAQ: BIIB) to $275.00 (from $400.00) while maintaining a Outperform rating after the company announced that the Ph. III ENGAGE and EMERGE studies of aducanumab for the treatment of cognitive impairment and dementia in Alzheimer's... More
Biogen (BIIB) fair value is $241/share without AD - Citi
March 21, 2019 8:28 AM EDTCiti analyst Robyn Karnauskas said Biogen (NASDAQ: BIIB) fair value is $241/share without AD
Biogen (BIIB) PT Lowered to $250 at Baird on Alzheimer's Failure
March 21, 2019 8:20 AM EDTBaird analyst Brian Skorney lowered the price target on Biogen (NASDAQ: BIIB) to $250.00 (from $348.00) while maintaining a Neutral rating.
Skorney commented, "We are cutting our price target to $250 on the failure of aducanumab. The big question here is, where is the backstop? BIIB... More
